Clinical features of 76 patients surviving more than 3 months after allo-SCT and 18 patients with LONIPCs
. | All patients, N = 76 . | . | Patients with LONIPCs, N = 18 . | . | ||
|---|---|---|---|---|---|---|
| Clinical feature . | n . | % . | n . | % . | ||
| Sex | ||||||
| Male | 52 | 68.4 | 12 | 66.7 | ||
| Female | 24 | 31.6 | 6 | 33.3 | ||
| Median age, y (range) | 31.9 (15-51) | — | 34.8 (15-50) | — | ||
| Diagnosis | ||||||
| AML | 20 | 26.3 | 6 | 33.3 | ||
| ALL | 18 | 23.7 | 3 | 16.7 | ||
| CML | 19 | 25.0 | 1 | 5.6 | ||
| NHL | 7 | 9.2 | 5 | 27.8 | ||
| AA | 3 | 3.9 | 1 | 5.6 | ||
| MDS | 5 | 6.6 | 2 | 11.1 | ||
| Others | 4 | 5.3 | 0 | 0 | ||
| Transplant source Related donor | ||||||
| BM | 9 | 11.8 | 1 | 5.6 | ||
| PBSCs | 18 | 23.7 | 6 | 33.3 | ||
| BM plus PBSCs | 1 | 1.3 | 0 | 0 | ||
| Unrelated donor | ||||||
| BM | 47 | 61.8 | 11 | 61.1 | ||
| CB | 1 | 1.3 | 0 | 0 | ||
| HLA compatibility | ||||||
| Full match | 59 | 77.6 | 14 | 77.8 | ||
| Mismatch | 17 | 22.4 | 4 | 22.3 | ||
| 1 locus mismatch | 9 | 11.8 | 3 | 16.7 | ||
| 2 loci mismatch | 8 | 10.5 | 1 | 5.6 | ||
| ABO compatibility | ||||||
| Match | 48 | 63.2 | 13 | 72.2 | ||
| Mismatch | 28 | 36.8 | 5 | 27.8 | ||
| Sex compatibility | ||||||
| Match | 47 | 61.8 | 11 | 61.1 | ||
| Mismatch | 27 | 38.2 | 7 | 38.9 | ||
| Conditioning regimen | ||||||
| TBI/TLI regimen | 35 | 46.1 | 11 | 61.1 | ||
| Non-TBI/TLI regimen | 41 | 53.9 | 7 | 38.9 | ||
| GVHD prophylaxis | ||||||
| CsA with or without MTX | 60 | 78.9 | 16 | 88.9 | ||
| FK506 plus MTX | 16 | 21.1 | 2 | 11.1 | ||
| Acute GVHD | ||||||
| Grade 0 | 22 | 28.9 | 5 | 27.8 | ||
| Grade I | 25 | 32.9 | 5 | 27.8 | ||
| Grade II | 22 | 28.9 | 7 | 38.9 | ||
| Grades III-IV | 7 | 9.2 | 1 | 5.6 | ||
| cGVHD | ||||||
| 0 | 22 | 28.9 | 2 | 11.1 | ||
| Limited | 13 | 17.1 | 1 | 5.6 | ||
| Extensive | 37 | 48.7 | 15 | 83.3 | ||
| NE | 4 | 5.3 | 0 | 0 | ||
| cGVHD/liver | ||||||
| − | 40 | 52.6 | 9 | 50.0 | ||
| + | 32 | 42.1 | 9 | 50.0 | ||
| cGVHD/skin | ||||||
| − | 37 | 48.7 | 8 | 44.4 | ||
| + | 35 | 46.1 | 10 | 55.6 | ||
| cGVHD/sicca syndrome | ||||||
| − | 43 | 56.6 | 3 | 16.7 | ||
| + | 33 | 43.3 | 15 | 83.3 | ||
. | All patients, N = 76 . | . | Patients with LONIPCs, N = 18 . | . | ||
|---|---|---|---|---|---|---|
| Clinical feature . | n . | % . | n . | % . | ||
| Sex | ||||||
| Male | 52 | 68.4 | 12 | 66.7 | ||
| Female | 24 | 31.6 | 6 | 33.3 | ||
| Median age, y (range) | 31.9 (15-51) | — | 34.8 (15-50) | — | ||
| Diagnosis | ||||||
| AML | 20 | 26.3 | 6 | 33.3 | ||
| ALL | 18 | 23.7 | 3 | 16.7 | ||
| CML | 19 | 25.0 | 1 | 5.6 | ||
| NHL | 7 | 9.2 | 5 | 27.8 | ||
| AA | 3 | 3.9 | 1 | 5.6 | ||
| MDS | 5 | 6.6 | 2 | 11.1 | ||
| Others | 4 | 5.3 | 0 | 0 | ||
| Transplant source Related donor | ||||||
| BM | 9 | 11.8 | 1 | 5.6 | ||
| PBSCs | 18 | 23.7 | 6 | 33.3 | ||
| BM plus PBSCs | 1 | 1.3 | 0 | 0 | ||
| Unrelated donor | ||||||
| BM | 47 | 61.8 | 11 | 61.1 | ||
| CB | 1 | 1.3 | 0 | 0 | ||
| HLA compatibility | ||||||
| Full match | 59 | 77.6 | 14 | 77.8 | ||
| Mismatch | 17 | 22.4 | 4 | 22.3 | ||
| 1 locus mismatch | 9 | 11.8 | 3 | 16.7 | ||
| 2 loci mismatch | 8 | 10.5 | 1 | 5.6 | ||
| ABO compatibility | ||||||
| Match | 48 | 63.2 | 13 | 72.2 | ||
| Mismatch | 28 | 36.8 | 5 | 27.8 | ||
| Sex compatibility | ||||||
| Match | 47 | 61.8 | 11 | 61.1 | ||
| Mismatch | 27 | 38.2 | 7 | 38.9 | ||
| Conditioning regimen | ||||||
| TBI/TLI regimen | 35 | 46.1 | 11 | 61.1 | ||
| Non-TBI/TLI regimen | 41 | 53.9 | 7 | 38.9 | ||
| GVHD prophylaxis | ||||||
| CsA with or without MTX | 60 | 78.9 | 16 | 88.9 | ||
| FK506 plus MTX | 16 | 21.1 | 2 | 11.1 | ||
| Acute GVHD | ||||||
| Grade 0 | 22 | 28.9 | 5 | 27.8 | ||
| Grade I | 25 | 32.9 | 5 | 27.8 | ||
| Grade II | 22 | 28.9 | 7 | 38.9 | ||
| Grades III-IV | 7 | 9.2 | 1 | 5.6 | ||
| cGVHD | ||||||
| 0 | 22 | 28.9 | 2 | 11.1 | ||
| Limited | 13 | 17.1 | 1 | 5.6 | ||
| Extensive | 37 | 48.7 | 15 | 83.3 | ||
| NE | 4 | 5.3 | 0 | 0 | ||
| cGVHD/liver | ||||||
| − | 40 | 52.6 | 9 | 50.0 | ||
| + | 32 | 42.1 | 9 | 50.0 | ||
| cGVHD/skin | ||||||
| − | 37 | 48.7 | 8 | 44.4 | ||
| + | 35 | 46.1 | 10 | 55.6 | ||
| cGVHD/sicca syndrome | ||||||
| − | 43 | 56.6 | 3 | 16.7 | ||
| + | 33 | 43.3 | 15 | 83.3 | ||
cGVHD indicates chronic GVHD; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; and AA, aplastic anemia.